Srinibas Pradhan Constructions IPO...
28 Feb, 2026
Sai Life Sciences Limited IPO
Incorporated in January 1999, Sai Life Sciences Limited has established itself as a prominent player in the research, development, and manufacturing of small-molecule new chemical entities. The company is renowned for delivering tailor-made services to biotech firms and global pharmaceutical giants, effectively supporting their innovative pursuits.
In the Financial Year 2024, Sai Life Sciences demonstrated its extensive reach and expertise by providing services to over 280 innovator pharmaceutical companies. Remarkably, in September 2024 alone, the company collaborated with more than 230 clients, showcasing its capacity to handle a high volume of projects efficiently. Among these esteemed clients, Sai Life Sciences proudly counts 18 of the top 25 pharmaceutical companies, based on their revenue in the calendar year 2023, underlining its reputation and trustworthiness in the industry.
Sai Life Sciences has strategically expanded its services to key markets, including the US, the UK, Europe, and Japan, ensuring global accessibility and influence. The company’s business development team is composed of 16 highly experienced and qualified professionals, with six stationed in the US, nine in the UK and Europe, and one in Japan. This diverse and strategically located team enables Sai Life Sciences to cater to the specific needs of clients in different regions effectively.
The company’s core service offerings include capabilities in chemistry, manufacturing, and control (CMC), as well as contract development and manufacturing organizations (CDMO). Additionally, Sai Life Sciences provides comprehensive contract research organization (CRO) services, featuring integrated discovery capabilities across biology, chemistry, drug metabolism, and pharmacokinetics. This extensive range of services positions Sai Life Sciences as a versatile and indispensable partner for pharmaceutical innovation.
Sai Life Sciences Limited IPO Overview:
- Issue Type: Combination of fresh issue and offer for sale (OFS)
- IPO Size: ₹3,042.62 crores
- Subscription Dates: Opens on December 11, 2024 and closes on December 13, 2024
- Fresh Issue: ₹950.00 crores (1.73 crore shares)
- Offer for Sale: ₹2,092.62 crores (3.81 crore shares)
- Price Per Share: ₹522 to ₹549 per share
- Minimum Lot Size: 27 shares per application
- Book Running Lead Managers: Kotak Mahindra Capital Company Limited, Jefferies India Private Limited, Morgan Stanley India Company Pvt Ltd and IIFL Securities Ltd.
- Registrar: Kfin Technologies Limited
WHAT IS GMP?
GMP (Grey Market Premium) is the difference between the IPO price and the grey market price. It is the premium amount paid for the traded IPO shares. It plays an important role in IPOs as it reflects how the IPO would react on the listing day.
A grey market is a place where shares/stocks are traded before being listed officially on the stock exchange.
Sai Life Sciences Limited IPO GMP
| GMP Date | IPO Price | GMP | Last Updated |
|---|---|---|---|
| - | 549 | - | - |
**The GMP prices displayed here are solely for informational purposes related to the grey market news. India IPO does not engage in or facilitate grey market trading, nor are these rates (sub2) indicative of any trading activity. We also do not recommend or endorse participation in the grey market.**
Sai Life Sciences Limited IPO Details
| Detail | Description |
|---|---|
| IPO Date | December 11, 2024 to December 13, 2024 |
| Listing Date | - |
| Face Value | ₹1 per share |
| Price Band | ₹522 to ₹549 per share |
| Lot Size | 27 Shares |
| Total Issue Size | 55,421,123 shares (aggregating up to ₹3,042.62 Cr) |
| Fresh Issue | 17,304,189 shares (aggregating up to ₹950.00 Cr) |
| Offer for Sale | 38,116,934 shares of ₹1 (aggregating up to ₹2,092.62 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
| Shareholding pre issue | 190,685,340 |
| Shareholding post issue | 207,989,529 |
Sai Life Sciences Limited IPO Timeline
| Detail | Description |
|---|---|
| IPO Open Date | Wednesday, December 11, 2024 |
| IPO Close Date | Friday, December 13, 2024 |
| Basis of Allotment | Monday, December 16, 2024 |
| Initiation of Refunds | Tuesday, December 17, 2024 |
| Credit of Shares to Demat | Tuesday, December 17, 2024 |
| Listing Date | Wednesday, December 18, 2024 |
| Cut-off time for UPI mandate confirmation | 5 PM on December 13, 2024 |
Sai Life Sciences Limited IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 27 | ₹14,823 |
| Retail (Max) | 13 | 351 | ₹192,699 |
| S-HNI (Min) | 14 | 378 | ₹207,522 |
| S-HNI (Max) | 67 | 1,809 | ₹993,141 |
| B-HNI (Min) | 68 | 1,836 | ₹1,007,964 |
Sai Life Sciences IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 50% of the Net Issue |
| Retail Shares Offered | Not less than 35% of the Net Issue |
| NII (HNI) Shares Offered | Not less than 15% of the Net Issue |
Sai Life Sciences Limited IPO Promoter Holding
| Share Holding Pre Issue | Share Holding Post Issue |
|---|---|
| 40.48% | - |
Competitive Strength:
- As an integrated CRDMO, the company provides a complete platform for discovery, development and manufacturing.
- CDMO platform with a diverse mix of commercial and under-development molecules.
- CRO services include integrated discovery capabilities across biology, chemistry and drug metabolism and pharmacokinetics.
Sai Life Sciences Limited IPO Financial Information
| Period Ended | Assets | Total Income | Profit After Tax | Net Worth | Reserves and Surplus | Total Borrowing | ||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 30 Sep 2024 | 2,476.78 | 693.35 | 28.01 | 1,044.75 | - | 764.49 | ||||||||||||||||||||||||||||||||||
| 31 Mar 2024 | 2,275.14 | 1,494.27 | 82.81 | 974.34 | - | 710.16 | ||||||||||||||||||||||||||||||||||
| 31 Mar 2023 | 2,186.65 | 1,245.11 | 9.99 | 887.29 | - | 699.23 | ||||||||||||||||||||||||||||||||||
| 31 Mar 2022 | 2,164.23 | 897.74 | 6.23 | 877.76 | - | 751.32 | ||||||||||||||||||||||||||||||||||
| Amount in ₹ Crore | ||||||||||||||||||||||||||||||||||||||||
Key Performance Indicator
| KPI | Values |
|---|---|
| ROE | 11.79% |
| ROCE | 15.96% |
| RoNW | 8.13% |
| P/BV | 10.18 |
| PAT Margin (%) | 5.65 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 4.34 | 2.69 |
| P/E (x) | 126.42 | 203.82 |
Sai Life Sciences IPO Objectives:-
- The company propose to utilise the Net Proceeds towards funding the following objectives:
- 1. Repayment/prepayment in full or part, of all or certain outstanding borrowings availed by the Company.
- 2. General corporate purposes.
DRHP:
View DRHPRead more :
- Ganesh Infraworld Limited IPO
- Vishal Mega Mart Limited IPO
- Afcons Infrastructure Limited IPO, GMP, Details, Price, And Review
Frequently Asked Questions (FAQs)
-
What is Sai Life Sciences IPO?
Sai Life Sciences IPO is a Mainboard IPO. The company is going to raise ₹3,042.62 Crores via IPO. The issue is priced at ₹522 to ₹549 per equity share. The IPO is to be listed on BSE & NSE.
-
When will the Sai Life Sciences IPO open for subscription?
The IPO is to open on December 11, 2024 for QIB, NII and Retail Investors. The IPO will close on December 13, 2024.
-
What is Sai Life Sciences IPO Investors Portion?
The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.
-
What is Sai Life Sciences IPO Issue Size?
Sai Life Sciences IPO issue size is ₹3,042.62 crores.
-
What is Sai Life Sciences IPO Price Band?
Sai Life Sciences IPO Price Band is ₹522 to ₹549.
